FDA approves expanded indication for Supernus’ Qelbree for ADHD

[cafead]

via The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.

article source